|
|
|
Products |
CAS No. |
Usage |
| 3,5-Dichlorobenzoyl chloride | 2905-62-6 | Tafamidis intermediate |
| 3,5-Dichlorobenzoic acid | 51-36-5 | Tafamidis intermediate |
| Tafamidis | 594839-88-0 | Tafamidis |
| Tafamidis meglumine | 951395-08-7 | Tafamidis meglumine |
| 2,4-Dichloro-1H-pyrrolo[2,3-d]pyrimidine | 90213-66-4 | Tofacitinib intermediate |
| N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine hydrochloride (1:2) | 1228879-37-5 | Tofacitinib intermediate |
| (3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine | 477600-70-7 | Tofacitinib intermediate |
| (3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine hydrochloride | 1062580-52-2 | Tofacitinib intermediate |
| (2R,3R)-2,3-Bis[(4-methylbenzoyl)oxy]butanedioic acid compd. with (3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine | 477600-71-8 | Tofacitinib intermidate |
| N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 477600-73-0 | Tofacitinib intermediate |
| cis-1-Benzyl-N-methyl-4-methylpiperidin-3-amine dihydrochloride | 477600-68-3 | |
| N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (N-1 BASE) | 477600-74-1 | Tofacitinib intermediate |
| N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-amine dihydrochloride (N-1 HCl) | 1260590-51-9 | Tofacitinib intermediate |
| Tofacitinib BASE | 477600-75-2 | Tofacitinib BASE |
| Tofacitinib Citratet | 540737-29-9 | Tofacitinib Citratet |
| 2,6-Dichlorobenzyl bromide | 20443-98-5 | Vilanterol intermidate |
| 2-bromo-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-Ethanone | 102293-80-1 | Vilanterol intermidate |
| tert-butyl 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethylcarbamate | 452339-71-8 | Vilanterol intermidate |
| tert-butyl (2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethylcarbamate | 452339-72-9 | Vilanterol intermidate |
| 5-(2,2-diMethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one | 452340-96-4 | Vilanterol intermidate |
|
|
中文 
English
